TARRYTOWN, N.Y. - Regeneron Pharmaceuticals said Monday that a single dose of its antibody treatment reduced the risk of contracting COVID-19 by 81.6% for up to eight months, according to its late-stage trial.
The company said the results could potentially pave the way for broader use in helping to protect certain people with weakened immune systems.The monoclonal antibody treatment, called REGEN-COV, is currently available under an emergency use authorization by the U.S.
Food and Drug Administration to treat patients with mild to moderate COVID-19 and are at risk of developing severe symptoms.
It has also received FDA emergency approval as a preventive treatment for some people at high risk for developing severe COVID-19, are not fully.